Tower Research Capital (TRC)’s Acrivon Therapeutics ACRV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $10.5K | Buy |
8,844
+5,754
| +186% | +$6.85K | ﹤0.01% | 3944 |
|
|
2025
Q1 | $6.27K | Buy |
3,090
+1,324
| +75% | +$2.69K | ﹤0.01% | 4055 |
|
|
2024
Q4 | $10.6K | Sell |
1,766
-2,989
| -63% | -$18K | ﹤0.01% | 3789 |
|
|
2024
Q3 | $33.3K | Buy |
4,755
+976
| +26% | +$6.83K | ﹤0.01% | 2947 |
|
|
2024
Q2 | $21.9K | Buy |
3,779
+2,962
| +363% | +$17.2K | ﹤0.01% | 3705 |
|
|
2024
Q1 | $5.84K | Sell |
817
-1,201
| -60% | -$8.59K | ﹤0.01% | 4481 |
|
|
2023
Q4 | $9.93K | Buy |
2,018
+763
| +61% | +$3.75K | ﹤0.01% | 4326 |
|
|
2023
Q3 | $12K | Buy |
1,255
+523
| +71% | +$5K | ﹤0.01% | 3936 |
|
|
2023
Q2 | $9.49K | Sell |
732
-360
| -33% | -$4.67K | ﹤0.01% | 4250 |
|
|
2023
Q1 | $14K | Buy |
1,092
+933
| +587% | +$12K | ﹤0.01% | 3856 |
|
|
2022
Q4 | $2K | Buy |
+159
| New | +$2K | ﹤0.01% | 5315 |
|